229 related articles for article (PubMed ID: 12651270)
21. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation.
Serrano D; Carrión R; Balsalobre P; Miralles P; Berenguer J; Buño I; Gómez-Pineda A; Ribera JM; Conde E; Díez-Martín JL;
Exp Hematol; 2005 Apr; 33(4):487-94. PubMed ID: 15781340
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of severe systemic autoimmune diseases with autologous peripheral blood stem cell transplantation].
Zhao Y; Zhou DB; Leng XM; Wang SJ; Li TS; Duan Y; Shen T; Zhao YQ; Zhang JP; Bai LJ; Cui W; Zhang FQ; Zeng XF; Zhang FC; Dong Y; Tang FL
Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(24):2077-81. PubMed ID: 15730620
[TBL] [Abstract][Full Text] [Related]
23. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study.
Fassas A; Anagnostopoulos A; Kazis A; Kapinas K; Sakellari I; Kimiskidis V; Tsompanakou A
Bone Marrow Transplant; 1997 Oct; 20(8):631-8. PubMed ID: 9383225
[TBL] [Abstract][Full Text] [Related]
24. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
[TBL] [Abstract][Full Text] [Related]
25. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
[TBL] [Abstract][Full Text] [Related]
26. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
[TBL] [Abstract][Full Text] [Related]
27. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
Perfetti V; Siena S; Palladini G; Bregni M; Di Nicola M; Obici L; Magni M; Brunetti L; Gianni AM; Merlini G
Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
[TBL] [Abstract][Full Text] [Related]
28. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma.
Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP
Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718
[TBL] [Abstract][Full Text] [Related]
29. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
Ozakbas S; Ormeci B; Idiman E
J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
[TBL] [Abstract][Full Text] [Related]
30. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation.
Fagius J; Lundgren J; Oberg G
Mult Scler; 2009 Feb; 15(2):229-37. PubMed ID: 18805841
[TBL] [Abstract][Full Text] [Related]
31. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience.
Krasulová E; Trneny M; Kozák T; Vacková B; Pohlreich D; Kemlink D; Kobylka P; Kovárová I; Lhotáková P; Havrdová E
Mult Scler; 2010 Jun; 16(6):685-93. PubMed ID: 20350962
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
[TBL] [Abstract][Full Text] [Related]
33. Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma.
Annunziata M; Celentano M; Pocali B; D'Amico MR; Palmieri S; Viola A; Copia C; Falco C; Del Vecchio L; Ferrara F
Ann Hematol; 2006 Jun; 85(6):394-9. PubMed ID: 16538502
[TBL] [Abstract][Full Text] [Related]
34. Intense immunosuppressive therapy followed by autologous peripheral blood selected progenitor cell reinfusion for severe autoimmune disease.
Musso M; Porretto F; Crescimanno A; Bondi F; Polizzi V; Scalone R
Am J Hematol; 2001 Feb; 66(2):75-9. PubMed ID: 11421302
[TBL] [Abstract][Full Text] [Related]
35. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial.
Brinkman DM; de Kleer IM; ten Cate R; van Rossum MA; Bekkering WP; Fasth A; van Tol MJ; Kuis W; Wulffraat NM; Vossen JM
Arthritis Rheum; 2007 Jul; 56(7):2410-21. PubMed ID: 17599770
[TBL] [Abstract][Full Text] [Related]
36. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
37. [Clinical observation of selected CD34(+) cell autologous transplantation in non-Hodgin lymphoma: report of 5 cases].
You Y; Xia LH; Zhang C; Liu F; Chen ZC; Zou P
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3127-9. PubMed ID: 18269872
[TBL] [Abstract][Full Text] [Related]
38. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
39. [Transplantation of purified CD34+ stem cells from autologous peripheral blood for treatment of systemic lupus erythematosus].
Zeng K; Peng XB; Sun J; Xu D; Meng FY
Di Yi Jun Yi Da Xue Xue Bao; 2002 Nov; 22(11):1052. PubMed ID: 12433652
[TBL] [Abstract][Full Text] [Related]
40. Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution.
Magagnoli M; Castagna L; Balzarotti M; Sarina B; Timofeeva I; Bertuzzi A; Compasso S; Nozza A; Siracusano L; Santoro A
Am J Hematol; 2003 Aug; 73(4):267-72. PubMed ID: 12879431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
